MELANIA DIRCE OLIVEIRA MARQUES
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Phenotyping Pharyngeal Pathophysiology using Polysomnography in Patients with Obstructive Sleep Apnea(2018) SANDS, Scott A.; EDWARDS, Bradley A.; TERRILL, Philip I.; TARANTO-MONTEMURRO, Luigi; AZARBARZIN, Ali; MARQUES, Melania; HESS, Lauren B.; WHITE, David P.; WELLMAN, AndrewRationale: Therapies for obstructive sleep apnea (OSA) could be administered on the basis of a patient's own phenotypic causes (""traits"") if a clinically applicable approach were available. Objectives: Here we aimed to provide a means to quantify two key contributors to OSA-pharyngeal collapsibility and compensatory muscle responsiveness-that is applicable to diagnostic polysomnography. Methods: Based on physiological definitions, pharyngeal collapsibility determines the ventilation at normal (eupneic) ventilatory drive during sleep, and pharyngeal compensation determines the rise in ventilation accompanying a rising ventilatory drive. Thus, measuring ventilation and ventilatory drive (e.g., during spontaneous cyclic events) should reveal a patient's phenotypic traits without specialized intervention. We demonstrate this concept in patients with OSA (N = 29), using a novel automated noninvasive method to estimate ventilatory drive (polysomnographic method) and using ""gold standard"" ventilatory drive (intraesophageal diaphragm EMG) for comparison. Specialized physiological measurements using continuous positive airway pressure manipulation were employed for further comparison. The validity of nasal pressure as a ventilation surrogate was also tested (N = 11). Measurements and Main Results: Polysomnography-derived collapsibility and compensation estimates correlated favorably with those quantified using gold standard ventilatory drive (R = 0.83, P < 0.0001; and R = 0.76, P < 0.0001; respectively) and using continuous positive airway pressuremanipulation (R = 0.67, P < 0.0001; and R = 0.64, P < 0.001; respectively). Polysomnographic estimates effectively stratified patients into high versus low subgroups (accuracy, 69-86% vs. ventilatory drive measures; P < 0.05). Traits were near-identical using nasal pressure versus pneumotach (N = 11, R >= 0.98, both traits; P < 0.001). Conclusions: Phenotypes of pharyngeal dysfunction in OSA are evident from spontaneous changes in ventilation and ventilatory drive during sleep, enabling noninvasive phenotyping in the clinic. Our approach may facilitate precision therapeutic interventions for OSA.
conferenceObject Simplified OSA Phenotyping of Respiratory Events for Predicting Oral Appliance Efficacy(2019) VENA, D.; AZARBARZIN, A.; EDWARDS, B. A.; RADMAND, R.; MARQUES, M.; TARANTO-MONTEMURRO, L. T.; CALIANESE, N.; WHITE, D.; LANDRY, S.; JOOSTEN, S. A.; HAMILTON, G.; THOMSON, L.; SANDS, S. A.; WELLMAN, D.conferenceObject Retropalatal and Retroglossal Airway Compliance and Negative Effort Dependence in Patients with Obstructive Sleep Apnea(2018) MARQUES, M. O.; GENTA, P.; AZARBARZIN, A.; SANDS, S. A.; TARANTO-MONTEMURRO, L. T.; MESSINEO, L.; WHITE, D.; WELLMAN, A.conferenceObject Clinical Predictors of Respiratory System Loop Gain in Healthy Subjects and Patients with Obstructive Sleep Apnea(2018) MESSINEO, L.; TARANTO-MONTEMURRO, L. T.; AZARBARZIN, A.; MARQUES, M.; CALIANESE, N.; WHITE, D. P.; SANDS, S. A.; WELLMAN, A.- The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity A Randomized, Placebo-controlled, Double-Blind Crossover Trial(2019) TARANTO-MONTEMURRO, Luigi; MESSINEO, Ludovico; SANDS, Scott A.; AZARBARZIN, Ali; MARQUES, Melania; EDWARDS, Bradley A.; ECKERT, Danny J.; WHITE, David P.; WELLMAN, AndrewRationale: There is currently no effective pharmacological treatment for obstructive sleep apnea (OSA). Recent investigations indicate that drugs with noradrenergic and antimuscarinic effects improve genioglossus muscle activity and upper airway patency during sleep. Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in people with OSA. Methods: A total of 20 people completed a randomized, placebo-controlled, double-blind, crossover trial comparing 1 night of 80 mg atomoxetine plus 5 mg oxybutynin (ato-oxy) to placebo administered before sleep. The AHI and genioglossus muscle responsiveness to negative esophageal pressure swings were measured via in-laboratory polysomnography. In a subgroup of nine patients, the AHI was also measured when the drugs were administered separately. Measurements and Main Results: The participants' median (interquartile range) age was 53 (46-58) years and body mass index was 34.8 (30.0-40.2) kg/m(2). ato-oxy lowered AHI by 63% (34-86%), from 28.5 (10.9-51.6) events/h to 7.5 (2.4-18.6) events/h (P < 0.001). Of the 15/20 patients with OSA on placebo (AHI > 10 events/hr), AHI was lowered by 74% (62-88%) (P < 0.001) and all 15 patients exhibited a >= 50% reduction. Genioglossus responsiveness increased approximately threefold, from 2.2 (1.1-4.7)%/cm H2O on placebo to 6.3 (3.0 to 18.3)%/cm H2O on ato-oxy (P < 0.001). Neither atomoxetine nor oxybutynin reduced the AHI when administered separately. Conclusions: A combination of noradrenergic and antimuscarinic agents administered orally before bedtime on 1 night greatly reduced OSA severity. These findings open new possibilities for the pharmacologic treatment of OSA.
conferenceObject Loop Gain in REM Versus Non-REM Sleep Using CPAP Manipulation(2019) MESSINEO, L.; MONTEMURRO, L. Taranto; AZARBARZIN, A.; MARQUES, M.; CALIANESE, N.; WHITE, D. P.; WELLMAN, D.; SANDS, S. A.